The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvement Act and other customary closing conditions.
Cowen and Company is acting as exclusive financial advisor to Victory and UBS Investment Bank is acting as exclusive financial advisor to Sciele in the transaction.
Victory’s lead product is Naprelan, a branded non-steroidal anti-inflammatory drug (NSAID).
Ed Schutter, President and COO of Sciele, said: “The acquisition of Victory is another important step in the implementation of Sciele’s strategic plan to further diversify our product portfolio and generate additional growth for Sciele. This acquisition provides an immediate expansion into the pain market for Sciele, establishes a platform from which to acquire additional pain management products and aligns Sciele with Shionogi’s focus in pain management.”
Matt Heck, President and CEO of Victory, said: “We have built an outstanding pain franchise and believe that Sciele has the resources to maximize the potential of Victory’s marketed products and its research and development pipeline.”